Publication Information

{'id': 'https://openalex.org/W2055087388', 'doi': 'https://doi.org/10.1212/wnl.51.2.649', 'title': "Suprathreshold levodopa doses, dyskinesias, and disability in advanced Parkinson's disease", 'display_name': "Suprathreshold levodopa doses, dyskinesias, and disability in advanced Parkinson's disease", 'publication_year': 1998, 'publication_date': '1998-08-01', 'ids': {'openalex': 'https://openalex.org/W2055087388', 'doi': 'https://doi.org/10.1212/wnl.51.2.649', 'mag': '2055087388', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/9710072'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.1212/wnl.51.2.649', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S79704628', 'display_name': 'Neurology', 'issn_l': '0028-3878', 'issn': ['0028-3878', '1526-632X'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310315671', 'host_organization_name': 'Lippincott Williams & Wilkins', 'host_organization_lineage': ['https://openalex.org/P4310315671', 'https://openalex.org/P4310318547'], 'host_organization_lineage_names': ['Lippincott Williams & Wilkins', 'Wolters Kluwer'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'letter', 'type_crossref': 'journal-article', 'indexed_in': ['crossref', 'pubmed'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5109802377', 'display_name': 'M.W.I.M. Horstink', 'orcid': None}, 'institutions': [], 'countries': ['NL'], 'is_corresponding': False, 'raw_author_name': 'Martin W.I.M. Horstink', 'raw_affiliation_strings': ['Nijmegen, the Netherlands'], 'affiliations': [{'raw_affiliation_string': 'Nijmegen, the Netherlands', 'institution_ids': []}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5023933287', 'display_name': 'Peter Praamstra', 'orcid': None}, 'institutions': [], 'countries': ['NL'], 'is_corresponding': False, 'raw_author_name': 'Peter Praamstra', 'raw_affiliation_strings': ['Nijmegen, the Netherlands'], 'affiliations': [{'raw_affiliation_string': 'Nijmegen, the Netherlands', 'institution_ids': []}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 0, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': None, 'has_fulltext': True, 'fulltext_origin': 'ngrams', 'cited_by_count': 2, 'citation_normalized_percentile': {'value': 0.285097, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 63, 'max': 67}, 'biblio': {'volume': '51', 'issue': '2', 'first_page': '649', 'last_page': '649'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10085', 'display_name': "Parkinson's Disease Mechanisms and Treatments", 'score': 0.9997, 'subfield': {'id': 'https://openalex.org/subfields/2728', 'display_name': 'Neurology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10085', 'display_name': "Parkinson's Disease Mechanisms and Treatments", 'score': 0.9997, 'subfield': {'id': 'https://openalex.org/subfields/2728', 'display_name': 'Neurology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10919', 'display_name': 'Neurological disorders and treatments', 'score': 0.9915, 'subfield': {'id': 'https://openalex.org/subfields/2728', 'display_name': 'Neurology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10660', 'display_name': 'Conducting polymers and applications', 'score': 0.974, 'subfield': {'id': 'https://openalex.org/subfields/2507', 'display_name': 'Polymers and Plastics'}, 'field': {'id': 'https://openalex.org/fields/25', 'display_name': 'Materials Science'}, 'domain': {'id': 'https://openalex.org/domains/3', 'display_name': 'Physical Sciences'}}], 'keywords': [], 'concepts': [{'id': 'https://openalex.org/C2780304432', 'wikidata': 'https://www.wikidata.org/wiki/Q300989', 'display_name': 'Levodopa', 'level': 4, 'score': 0.97768366}, {'id': 'https://openalex.org/C2780405171', 'wikidata': 'https://www.wikidata.org/wiki/Q629444', 'display_name': 'Dyskinesia', 'level': 4, 'score': 0.89089584}, {'id': 'https://openalex.org/C2776525014', 'wikidata': 'https://www.wikidata.org/wiki/Q1531991', 'display_name': 'Parkinsonism', 'level': 3, 'score': 0.81332093}, {'id': 'https://openalex.org/C2779734285', 'wikidata': 'https://www.wikidata.org/wiki/Q11085', 'display_name': "Parkinson's disease", 'level': 3, 'score': 0.68645215}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.5742878}, {'id': 'https://openalex.org/C2777427615', 'wikidata': 'https://www.wikidata.org/wiki/Q954257', 'display_name': 'Degenerative disease', 'level': 3, 'score': 0.4380188}, {'id': 'https://openalex.org/C2779134260', 'wikidata': 'https://www.wikidata.org/wiki/Q12136', 'display_name': 'Disease', 'level': 2, 'score': 0.396695}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.29006544}], 'mesh': [{'descriptor_ui': 'D000978', 'descriptor_name': 'Antiparkinson Agents', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D006233', 'descriptor_name': 'Disabled Persons', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': True}, {'descriptor_ui': 'D004409', 'descriptor_name': 'Dyskinesia, Drug-Induced', 'qualifier_ui': 'Q000209', 'qualifier_name': 'etiology', 'is_major_topic': True}, {'descriptor_ui': 'D007980', 'descriptor_name': 'Levodopa', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D010300', 'descriptor_name': 'Parkinson Disease', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': True}, {'descriptor_ui': 'D000978', 'descriptor_name': 'Antiparkinson Agents', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D004305', 'descriptor_name': 'Dose-Response Relationship, Drug', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D004409', 'descriptor_name': 'Dyskinesia, Drug-Induced', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006801', 'descriptor_name': 'Humans', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D007980', 'descriptor_name': 'Levodopa', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D010300', 'descriptor_name': 'Parkinson Disease', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D012189', 'descriptor_name': 'Retrospective Studies', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}], 'locations_count': 2, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.1212/wnl.51.2.649', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S79704628', 'display_name': 'Neurology', 'issn_l': '0028-3878', 'issn': ['0028-3878', '1526-632X'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310315671', 'host_organization_name': 'Lippincott Williams & Wilkins', 'host_organization_lineage': ['https://openalex.org/P4310315671', 'https://openalex.org/P4310318547'], 'host_organization_lineage_names': ['Lippincott Williams & Wilkins', 'Wolters Kluwer'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/9710072', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'display_name': 'Good health and well-being', 'score': 0.62, 'id': 'https://metadata.un.org/sdg/3'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 2, 'referenced_works': ['https://openalex.org/W1989063226', 'https://openalex.org/W2036314477'], 'related_works': ['https://openalex.org/W3148586516', 'https://openalex.org/W2529791985', 'https://openalex.org/W2465771749', 'https://openalex.org/W2416992253', 'https://openalex.org/W2315774369', 'https://openalex.org/W2163965390', 'https://openalex.org/W2124414252', 'https://openalex.org/W2110669321', 'https://openalex.org/W2042115553', 'https://openalex.org/W1975681203'], 'abstract_inverted_index': {'To': [0], 'the': [1, 25, 33, 51, 56, 87], 'Editor:': [2], 'In': [3], 'their': [4], 'article': [5], 'on': [6, 11], 'effects': [7], 'of': [8, 27, 45, 53], 'suprathreshold': [9], 'levodopa': [10, 28, 46, 82, 88], 'dyskinesia': [12], 'in': [13, 64], 'advanced': [14], "Parkinson's": [15], 'disease': [16], '(PD),': [17], 'Verhagen': [18], 'Metman': [19], 'et': [20], 'al.': [21], 'show': [22], 'that': [23, 63], 'increasing': [24, 80], 'dose': [26, 47], 'will': [29], 'steeply': [30], 'increase': [31, 44], 'both': [32], 'antiparkinsonian': [34, 57], 'and': [35], 'dyskinetic': [36], 'response': [37, 58], 'until': [38], 'plateau': [39], 'levels': [40], 'are': [41], 'reached.1': [42], 'Further': [43], 'does': [48], 'not': [49], 'aggravate': [50], 'severity': [52], 'dyskinesia,': [54], 'but': [55], 'duration': [59], 'increases.': [60], 'This': [61, 90], 'implies': [62], 'fluctuating': [65], 'patients': [66], 'with': [67], 'disabling': [68], 'end-of-dose': [69], 'parkinsonism,': [70], 'it': [71], 'may': [72], 'be': [73], 'better': [74], 'to': [75, 94], 'bring': [76], 'about': [77], 'improvement': [78], 'by': [79], 'individual': [81], 'doses': [83], 'rather': [84], 'than': [85], 'fractionating': [86], 'doses.': [89], 'conclusion,': [91], 'however,': [92], 'appears': [93], '…': [95]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2055087388', 'counts_by_year': [], 'updated_date': '2024-12-11T06:04:41.459726', 'created_date': '2016-06-24'}